NionyxBio

Engineering the future of gene therapy — capsid, cassette, delivery. Purpose built for precision & safety. Starting with the kidney.

[NionyxBio @NionyxBio]

Nionyx Bio is heading to the Cell & Gene Meeting on the Mesa.

Co-Founder & CEO Magdalena Tyrpien will present during the Innovation Spotlight on Oct. 5 at 2:45 PM in FLW Ballroom G.

Engineering gene therapy for the kidney.

#MeetingOnTheMesa #GeneTherapy #NionyxBio @Mtyrpien

[Dyno Therapeutics, Inc. @Dyno_Tx]

The Genetic Agency Technology Conference (GATC) takes place on November 18 in San Francisco.

Curious to join the patients, AI pioneers, technologists, entrepreneurs, and therapeutic developers rolling up their sleeves to find new cures for genetic disease?

@Mtyrpien of @Nionyxbio shares why this matters:

[NionyxBio @NionyxBio]

Proud to sponsor Alport Connect 2026. Grateful to be in the room with this community. #AlportConnect @AlportSyndFndn

[Magdalena Tyrpien @Mtyrpien]

It was a packed Bio Convention 2026! As always so great to share what we are building at @NionyxBio, the next gene therapy kidney company, with a pipeline built from our next generation AAVs selected from a human whole kidney explant. We are so excited to see what’s next! 🚀

And a special shoutout to Leighanne Oh, Helen Siaw, and Emily Park. Leighanne hosted a great Breaking 7% panel that brought together top minds sharing their stories

[NionyxBio @NionyxBio]

Nionyx Bio is heading to ASGCT 2026, presenting two posters that advance our vision of redefining gene therapy for the kidney.

Catch us at the Poster Reception on Wednesday, May 13, 5:00-6:30 PM in the Exhibit Hall. If you're attending, reach out to connect!

[NionyxBio @NionyxBio]

@2048vc Thank you for the shoutout!

[2048 Ventures 🧬 🤖 ⚙️ @2048vc]

🗞️ 2048 Ventures Portfolio Company News:

Nionyx Bio's kidney gene therapy wins the 2026 BIO-Europe Spring Startup Spotlight

https://t.co/r3m7apcyVg

@NionyxBio // @2048vc // #startups // #VC

[Magdalena Tyrpien @Mtyrpien]

@NionyxBio won 1st place at the BIO-Europe Spring Startup Spotlight yesterday in Lisbon. 🏆

What a week. Incredible to be here with my Co-founder & CTO Leszek Lisowski!

We’re building next-generation AAV gene therapy for the kidney. Proprietary capsids screened from human kidney tissue. Pipeline starting with Alport syndrome. Kidney-first, from day one.

Onward. 🚀

[NionyxBio @NionyxBio]

Nionyx Bio won 1st place at the BIO-Europe Spring Startup Spotlight yesterday in Lisbon. 🏆

We're building next-generation AAV gene therapy for the kidney. Proprietary capsids screened from human kidney tissue. Pipeline starting with Alport syndrome. Onward!

[NionyxBio @NionyxBio]

RT @Mtyrpien: Yesterday I attended the first-ever @CNBC cures summit, hosted by @BeckyQuick and put together by her and husband, Matt Quayl…

[NionyxBio @NionyxBio]

Today is #RareDiseaseDay.

There are over 150 rare kidney diseases, many genetic.

At Nionyx, we're building the platform that changes that. Precision gene therapy for kidney diseases long left behind.

We're in it for them.

#RDD2026 #GeneTherapy #KidneyDisease #alportsyndrome

[Magdalena Tyrpien @Mtyrpien]

Great seeing friends and colleagues and joining the Gene Therapy 2.0 panel at #ATW2026

Learning from the past. Building what’s next!

With @ForgeBio + @RayTherapeutics . #GeneTherapy #AAV @NionyxBio

[NionyxBio @NionyxBio]

We’ll be at Advanced Therapies Week in San Diego (Feb 9–12).

Catch our panel: Gene Therapy’s Second Act: Scaling for Sustainable Impact
Feb 10 | 2:15 PM PT

@ForgeBio @RayTherapeutics

#ATW26 #GeneTherapy #AAV #AdvancedTherapies

[Alex Iskold | 2048.vc @alexiskold]

I am thrilled to share that we raised an oversubscribed $82M Fund III to lead pre-seed and seed rounds in Vertical AI, Deep Tech, Healthcare and Biotech startups in NYC and Boston.

To be exact, we raised $82,048,000 - a number that felt on-brand for a nerdy firm like ours that loves riddles, the future, Morse code, and Easter eggs.

We are immensely grateful to our LPs for their ongoing belief in our strategy and approach. We are equally grateful to the founders who have chosen to partner with us.

Here is 2048 Ventures Ventures Fund III in a nutshell:

- We back exceptional, ultra-competitive, visionary founders.

- We lead pre-seed and seed rounds with $500K - $3M checks.

- We invest in Vertical AI, Deep Tech, Healthcare and Biotech.

- We invest primarily in NYC and Boston.

- We seek businesses with strong data moats.

Read more about where we’re excited to invest:

https://t.co/upt3TpYLQt

If you are a builder and visionary looking for the highest conviction first-check investor, please reach out or re-share with your network!

[2048 Ventures 🧬 🤖 ⚙️ @2048vc]

We are thrilled to share that we raised an oversubscribed $82M Fund III to lead pre-seed and seed rounds in Vertical AI, Deep Tech, Healthcare and Biotech startups in NYC and Boston.

To be exact, we raised $82,048,000 - a number that felt on-brand for a nerdy firm like ours that loves riddles, the future, Morse code, and Easter eggs.

We are immensely grateful to our LPs for their ongoing belief in our strategy and approach. We are equally grateful to the founders who have chosen to partner with us.

Here is @2048vc Ventures Fund III in a nutshell:

- We back exceptional, ultra-competitive, visionary founders.
- We lead pre-seed and seed rounds with $500K - $3M checks.
- We invest in Vertical AI, Deep Tech, Healthcare and Biotech.
- We invest primarily in NYC and Boston.
- We seek businesses with strong data moats.

Read more about where we’re excited to invest: https://t.co/a32lJ93JvA

If you are a builder and visionary looking for the highest conviction first-check investor, please reach out.

[Magdalena Tyrpien @Mtyrpien]

Congrats to our seed lead, @2048vc on their oversubscribed $82M Fund III!They were our first check in, led our seed, and set the tone for how we want to build: high conviction, high standards, move fast. The team is brilliant, thoughtful, and relentless in the best way. Huge congrats to @alexiskold @JulieMarieWolf and @sperezbaos We are lucky to have such a likeminded partner in our corner at @NionyxBio lets go!!! 🚀🚀🚀

[Magdalena Tyrpien @Mtyrpien]

What an incredible #JPM26. Sprinting across SF between meetings, catching up with peers, partners, and collaborators.

The momentum behind curative, organ-specific gene therapy is real.

Exciting time to be building gene therapy for the kidney. 🚀 let’s go @NionyxBio

#GeneTherapy #Biotech #KidneyResearch

[Magdalena Tyrpien @Mtyrpien]

@LifeSciVC @AimeeRaleigh13 Couldn’t agree more on kidney. Precision targeting + gene therapy is the next frontier for GT, core to what we’re building at @NionyxBio!

[NionyxBio @NionyxBio]

First American Society of Nephrology✔️

At Nionyx, we are building next-generation kidney AAV therapies to help make a meaningful impact for patients. We are privileged and excited to be here. Onwards.

#asn #kidneytherapy #genetherapy

[NionyxBio @NionyxBio]

A very productive week for our team at the European Society of Gene and Cell Therapy (ESGCT) meeting in Spain!

We’re grateful for the incredible discussions with colleagues and collaborators who share our sense of urgency and alignment around accelerating progress!